

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

(37 CFR 1.98(b))



APPLICANT

Bondarev, et al.

FILING DATE

January 18, 2005

GROUP

Not Yet Assigned

U.S. PATENT DOCUMENTS

Examiner Initial	Cite No.	Patent Number	Issue Date	Patentee	Class/ Subclass	Filing Date
	AA	5,539,082	7/23/1996	Nielsen et al.		
	AB	5,714,331	2/3/1998	Buchardt et al.		
	AC	5,719,262	2/17/1998	Buchardt et al.		
	AD	6,046,307	4/4/2000	Shay et al.		
	AE	6,194,206	02/27/2001	West et al.		
	AF	6,156,763	12/05/2000	Kerwin et al.		
	AG	6,294,332	9/25/2001	Chabot		

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

Examiner Initial	Cite No.	Document Number	Publication Date	Country or Patent Office	Class/ Subclass	Translation Yes/No
	BA					
	BB					
	BC					

OTHER DOCUMENTS

(Including Author, Title, Date, Relevant Pages, Place of Publication)

Examiner Initial	Cite No.	
	CA	De Clercq, "Recent developments in the chemotherapy of HIV infections", Pure & Appl. Chem., Vol. 70, No. 3, pp. 567-577, 1998.
	CB	Yamaguchi, et al., "Telomerase-inhibitory effects of the triphosphate derivatives of some biologically active nucleosides", Nucleic Acids Research Supplement No. 1, pp. 211-212, 2001.
	CC	Bisoffi, et al., "Inhibition of Human Telomerase by a Retrovirus Expressing Telomeric Antisense RNA", European Journal of Cancer, Vol. 34, No. 8, pp. 1242-1249, 1998.
	CD	Roth, et al., "Telomerase is limiting the growth of acute myeloid leukemia cells", Leukemia, 17, pp. 2410-2417, 2003.
	CE	Damm, et al., "A highly selective telomerase inhibitor limiting human cancer cell proliferation", The EMBO Journal, Vol. 20, No. 24, pp. 6958-6968, 2001.
	CF	GeneBank GI:5070620, <a href="http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&amp;val=5070620">http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&amp;val=5070620</a> .

EXAMINER	DATE CONSIDERED

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE  
(MODIFIED) U.S. PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.  
04-40018-US1SER. NO.  
10/586,434INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

## APPLICANT

Bondarev, et al.

## FILING DATE

January 18, 2005

## GROUP

Not Yet Assigned

(37 CFR 1.98(b))

## U.S. PATENT DOCUMENTS

Examiner Initial	Cite No.	Patent Number	Issue Date	Patentee	Class/ Subclass	Filing Date
	AH	6,723,712	4/20/2004	Bourhis et al.		
	AI	5,707,795	01/13/1998	West et al.		
	AJ	6,004,939	12/21/1999	Chen et al.		

## FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

Examiner Initial	Cite No.	Document Number	Publication Date	Country or Patent Office	Class/ Subclass	Translation Yes/No
	BD					
	BE					
	BF					

## OTHER DOCUMENTS

(Including Author, Title, Date, Relevant Pages, Place of Publication)

Examiner Initial	Cite No.	
	CG	Kimberland, et al., "Full-length human L 1 insertions retain the capacity for high frequency retrotransposition in cultured cells", Human Molecular Genetics, 1999, Vol. 8, No. 8, pp. 1557-1560.
	CH	Dorafshar, et al., "Vascular Endothelial Growth Factor Inhibits Mitogen-Induced Vascular Smooth Muscle Cell Proliferation", Journal of Surgical Research, 114, pp. 179-186, 2003.
	CI	Yang, et al., "Effects of GM-CSF, IL-3, and GM-CSF/ IL-3 fusion protein on apoptosis of human myeloid leukemic cell line Tf-1 induced by irradiation", Acta Pharmacol Sin 2004 Jan; 25 (1): 68-75.
	CJ	Schwahn, et al., "Positional cloning of the gene for X-linked retinitis pigmentosa 2", Nature Genetics, Vol. 19, August 1998, pp. 327-332.
	CK	Holmes, et al., "A new retrotransposable human L1 element from the LRE2 locus on chromosome 1q produces a chimaeric insertion", Nature Genetics, Vol. 7, June 1994.

EXAMINER	DATE CONSIDERED

**EXAMINER:** Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE  
(MODIFIED) U.S. PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.  
04-40018-US1SER. NO.  
10/586,434INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

## APPLICANT

Bondarev, et al.

## FILING DATE

January 18, 2005

## GROUP

Not Yet Assigned

(37 CFR 1.98(b))

## U.S. PATENT DOCUMENTS

Examiner Initial	Cite No.	Patent Number	Issue Date	Patentee	Class/ Subclass	Filing Date
	AK	6,995,145	2/2006	Au et al.		
	AL	6,365,578	4/2002	Calabresi et al.		
	AM	5,683,990	11/1997	Rideout et al.		

## FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

Examiner Initial	Cite No.	Document Number	Publication Date	Country or Patent Office	Class/ Subclass	Translation Yes/No
	BG					
	BH					
	BI					

## OTHER DOCUMENTS

(Including Author, Title, Date, Relevant Pages, Place of Publication)

Examiner Initial	Cite No.	
	CL	Yoshida, et al., "Insertional mutation by transposable element, L1, in the DMD gene results in X-linked dilated cardiomyopathy", Human Molecular Genetics, 1998, Vol. 7, No. 7, pp. 1129-1132.
	CM	Brouha, et al., "Evidence Consistent with Human L1 Retrotransposition in Maternal Meiosis I, Am J. Hum. Genet. Vol. 71, pp. 327-336, 2002.
	CN	Atlschul et al., "Gapped BLAST and PSI-BLAST: a new generation of protein database search programs", Nucleic Acids Research, Vol. 25, No. 17 pp. 3389-3402, 1997.
	CO	Ahlquist, "RNA-Dependant RNA Polymerases, Viruses, and RNA Silencing", Science, Vol. 296 pp. 1270-1273, May 17, 2002.
	CP	Yeager, et al., "Telomerase-negative Immortalized Human Cells Contain a Novel Type of Promyelocytic Leukemia (PML) Body" Cancer Research, Vol. 59, pp. 4175-4179, September 1, 1999.
	CQ	Rudolph, et al., "Longevity, Stress Response, and Cancer in Aging Telomerase-Deficient Mice", Cell, Vol. 96, pp. 710-712, March 5, 1999.

EXAMINER	DATE CONSIDERED

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE  
(MODIFIED) U.S. PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.  
04-40018-US1SER. NO.  
10/586,434INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

## APPLICANT

Bondarev, et al.

## FILING DATE

January 18, 2005

## GROUP

Not Yet Assigned

(37 CFR 1.98(b))

## U.S. PATENT DOCUMENTS

Examiner Initial	Cite No.	Patent Number	Issue Date	Patentee	Class/ Subclass	Filing Date

## FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

Examiner Initial	Cite No.	Document Number	Publication Date	Country or Patent Office	Class/ Subclass	Translation Yes/No

## OTHER DOCUMENTS

(Including Author, Title, Date, Relevant Pages, Place of Publication)

Examiner Initial	Cite No.	
	CR	Wang, et al., "Prolonged and Inducible Transgene Expression in the Liver Using Gutless Adenovirus: A Potential Therapy for Liver Cancer", Gastroenterology, Vol. 126, pp. 278-289, 2004.
	CS	Bryan, et al., "Telomere Dynamics and Telomerase Activity In <i>In Vitro</i> Immortalised Human Cells, European Journal of Cancer, Vol. 33, No. 5, pp. 767-773, 1997.
	CT	Greider, et al., "Identification of a Specific Telomere Terminal Transferase Activity in Tetrahymena Extracts", Cell, Vol. 43, pp. 405-413, December 1985, (Part 1).
	CU	Kim, et al., "Specific Association of Human Telomerase Activity with Immortal Cells and Cancer", Science, Vol. 266, pp. 2011-2015, December 23, 1994.
	CV	Bryan, et al., "Evidence for an alternative mechanism for maintaining telomere length in human tumors and tumor-derived cell lines", Nature Medicine, Vol. 3, No. 11, pp. 1271-1274, November 1997.
	CW	Kazazian, Jr., et al., "The impact of L1 retrotransposons on the human genome", Nature Genetics, Vol. 19, pp. 19-24, May 1998.

EXAMINER	DATE CONSIDERED

**EXAMINER:** Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (MODIFIED) U.S. PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 04-40018-US1	SER. NO. 10/586,434
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	APPLICANT Bondarev, et al.	
	FILING DATE January 18, 2005	GROUP Not Yet Assigned
(37 CFR 1.98(b))		

## U.S. PATENT DOCUMENTS

Examiner Initial	Cite No.	Patent Number	Issue Date	Patentee	Class/ Subclass	Filing Date

## FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

Examiner Initial	Cite No.	Document Number	Publication Date	Country or Patent Office	Class/ Subclass	Translation Yes/No

## OTHER DOCUMENTS

(Including Author, Title, Date, Relevant Pages, Place of Publication)

Examiner Initial	Cite No.	
	CX	Nozawa, et al., "In vitro expansion of mammalian telomere repeats by DNA polymerase $\alpha$ -primase", Nucleic Acids Research, Vol. 28, No. 16, pp. 3117-3124, 2000.
	CY	Allshire, et al., "Human telomeres contain at least three types of G-rich repeat distributed non-randomly", Nucleic Acids Research, Vol. 17, No. 12, pp. 4611-4627, 1989.
	CZ	Hahn, et al., "Inhibition of telomerase limits the growth of human cancer cells", Nature Medicine, Vol. 5, No. 10, pp. 1164-1170, October 1999.
	CCA	Bryan, et al., "Telomere elongation in immortal human cells without detectable telomerase activity", The EMBO Journal, Vol. 14, No. 17, pp. 4240-4248, 1995.
	CCB	Gupta, et al., "Development of Retinoblastoma in the Absence of Telomerase Activity", Journal of the National Cancer Institute, Vol. 88, No. 16, August 21, 1996.
	CCC	Dunham, et al., "Telomere maintenance by recombination in human cells", Nature Genetics, Vol. 26, pp. 447-450, December 2000.

EXAMINER	DATE CONSIDERED

**EXAMINER:** Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE  
(MODIFIED) U.S. PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.  
04-40018-US1SER. NO.  
10/586,434INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

## APPLICANT

Bondarev, et al.

## FILING DATE

January 18, 2005

## GROUP

Not Yet Assigned

(37 CFR 1.98(b))

## U.S. PATENT DOCUMENTS

Examiner Initial	Cite No.	Patent Number	Issue Date	Patentee	Class/ Subclass	Filing Date

## FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

Examiner Initial	Cite No.	Document Number	Publication Date	Country or Patent Office	Class/ Subclass	Translation Yes/No

## OTHER DOCUMENTS

(Including Author, Title, Date, Relevant Pages, Place of Publication)

Examiner Initial	Cite No.	
	CCD	Clements, et al., "The human LINE-1 reverse transcriptase: effect of deletions outside the common reverse transcriptase domain", Nucleic Acids Research, Vol. 26, No. 15, pp. 3528-3535, 1998.
	CCE	Skowronski et al., "Expression of a cytoplasmic LINE-1 transcript is regulated in a human teratocarcinoma cell line", Proc. Natl. Acad. Sci. USA, Vol. 82, pp. 6050-6054, September 1985.
	CCF	Moran et al., "High Frequency Retrotransposition in Cultured Mammalian Cells", Cell, Vol. 87, pp. 917-927, November 29, 1996.
	CCG	Murakami, et al., "Inhibition of Telomerase Activity and Cell Proliferation by a Reverse Transcriptase Inhibitor in Gynaecological Cancer Cell Lines, European Journal of Cancer, Vol. 35, No. 6, pp. 1027-1034, 1999.
	CCH	Rufer, et al., "Telomere length dynamics in human lymphocyte subpopulations measured by flow cytometry", Nature Biotechnology, Vol. 16, p. 743-747, August 1998.
	CCI	Hultdin, et al., "Telomere analysis by fluorescence <i>in situ</i> hybridization and flow cytometry", Nucleic Acids Research, Vol. 26, No. 16, pp. 3651-3656, 1998.

EXAMINER

DATE CONSIDERED

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE  
(MODIFIED) U.S. PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.  
04-40018-US1SER. NO.  
10/586,434INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

## APPLICANT

Bondarev, et al.

## FILING DATE

January 18, 2005

## GROUP

Not Yet Assigned

(37 CFR 1.98(b))

## U.S. PATENT DOCUMENTS

Examiner Initial	Cite No.	Patent Number	Issue Date	Patentee	Class/ Subclass	Filing Date

## FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

Examiner Initial	Cite No.	Document Number	Publication Date	Country or Patent Office	Class/ Subclass	Translation Yes/No

## OTHER DOCUMENTS

(Including Author, Title, Date, Relevant Pages, Place of Publication)

Examiner Initial	Cite No.	
	CCJ	Perrem, et al. "Repression of an alternative mechanism for lengthening of telomeres in somatic cell hybrids", Oncogene, Vol. 18, pp. 3383-3390, 1999.
	CCK	Guiducci, et al., "Expression of mutant telomerase in immortal telomerase-negative human cells results in cell cycle deregulation, nuclear and chromosomal abnormalities and rapid loss of viability", Oncogene, Vol. 20, pp. 714-725, 2001.
	CCL	Craig, et al., "Effects of adenovirus-mediated p16 <sup>INK4A</sup> expression on cell cycle arrest are determined by endogenous p16 and Rb status in human cancer cells", Oncogene, Vol. 16, pp. 265-272, 1998.
	CCM	Ostertag, et al., "Determination of L1 retrotransposition kinetics in cultured cells", Nucleic Acids Research, Vol. 28, No. 6, pp. 1418-1423, 2000.
	CCN	Kuo, et al., "Expression of Transposon LINE-1 is Relatively Human-Specific and Function of the Transcripts May Be Proliferation-Essential, Biochemical and Biophysical Research Communications, 253, pp. 566-570 (1998).

EXAMINER	DATE CONSIDERED

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE  
(MODIFIED) U.S. PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.  
04-40018-US1SER. NO.  
10/586,434INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

## APPLICANT

Bondarev, et al.

## FILING DATE

January 18, 2005

## GROUP

Not Yet Assigned

(37 CFR 1.98(b))

## U.S. PATENT DOCUMENTS

Examiner Initial	Cite No.	Patent Number	Issue Date	Patentee	Class/ Subclass	Filing Date

## FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

Examiner Initial	Cite No.	Document Number	Publication Date	Country or Patent Office	Class/ Subclass	Translation Yes/No
	BS					

## OTHER DOCUMENTS

(Including Author, Title, Date, Relevant Pages, Place of Publication)

Examiner Initial	Cite No.	
	CCO	Hernandez, et al., "Systemic treatment modalities in the management of AIDS-related Kaposi's sarcoma", Journal of the European Academy of the Dermatology and Venerology, 9, 1997, pp. 44-49.
	CCP	Poirier, et al., "Perinatal genotoxicity and carcinogenicity of anti-retroviral nucleoside analog drugs", Toxicology and Applied Pharmacology, 199, 2004, pp. 151-161.
	CCQ	Langford, et al., "Regression of oral Kaposi's sarcoma in a case of AIDS on Zidovudine (AZT)", British Journal of Dermatology, vol. 120, 1989, pp. 709-713.
	CCR	Ofelia, et al., "Transplacental Effects of 3'-Azido-2', 3'-Dideoxythymidine (AZT): Tumorigenicity in Mice and Genotoxicity in Mice and Monkeys", Journal of the National Cancer Institute, Vol. 89, No. 21, November 5, 1997, pp. 1602-1618.
	CCS	Pluda, et al., "Parameters Affecting the Development of Non-Hodgkin's Lymphoma in Patients With Severe Human Immunodeficiency Virus Infection Receiving Antiretroviral Therapy", Journal of Clinical Oncology, Vol. 11, No. 6, June 1993, pp. 1099-1107.

EXAMINER	DATE CONSIDERED

**EXAMINER:** Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE  
(MODIFIED) U.S. PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.  
04-40018-US1SER. NO.  
10/586,434INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

## APPLICANT

Bondarev, et al.

## FILING DATE

January 18, 2005

## GROUP

Not Yet Assigned

(37 CFR 1.98(b))

## U.S. PATENT DOCUMENTS

Examiner Initial	Cite No.	Patent Number	Issue Date	Patentee	Class/ Subclass	Filing Date

## FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

Examiner Initial	Cite No.	Document Number	Publication Date	Country or Patent Office	Class/ Subclass	Translation Yes/No

## OTHER DOCUMENTS

(Including Author, Title, Date, Relevant Pages, Place of Publication)

Examiner Initial	Cite No.	
	CCT	Giordano, et al., "Reverse Transcriptase Activity in Mature Spermatozoa of Mouse", The Journal of Cell Biology, vol. 148, no. 6, March 20, 2000, pp. 1107-1113.
	CCU	Mangiacasale, et al., "Exposure of normal and transformed cells to nevirapine, a reverse transcriptase inhibitor, reduces cell growth and promotes differentiation", Oncogene, vol. 22, 2003, pp. 2750-2761.
	CCV	Beraldi, et al., "Expression of LINE-1 Retroposons Is Essential for Murine Preimplantation Development", Molecular Reproduction and Development, vol. 73, 2006, pp. 279-287.
	CCW	Soifer, et al., "A potential role for RNA interference in controlling the activity of the human LINE-1 retrotransposon", Nucleic Acids Research, vol. 33, no. 3, 2005, pp. 846-856.
	CCX	Sciamanna, et al., "Inhibition of endogenous reverse transcriptase antagonizes human tumor growth", Oncogene, vol. 24, 2005, pp. 3923-2931.
	CCY	Gellert et al., "Telomerase as a Therapeutic Target in Cancer," Drug Discovery Today: Disease Mechanisms, Vol. 2, No. 2, 2005, pp. 159-164.
	CCZ	Herbert et al., "Telomerase and Breast Cancer," Breast Cancer Res, Vol. 3, No. 3, 2001, pp. 146-149.
	DDA	Melana et al., "Inhibition of Cell Growth and Telomerase Activity of Breast Cancer Cells <i>in Vitro</i> by 3' -Azido-3' -deoxythymidine <sup>1</sup> ", Clinical Cancer Research, Vol. 4, March 1998, pp. 693-696.

EXAMINER	DATE CONSIDERED

**EXAMINER:** Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<b>FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (MODIFIED) U.S. PATENT AND TRADEMARK OFFICE</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (37 CFR 1.98(b))	<b>ATTY. DOCKET NO.</b> 04-40018-US1	<b>SER. NO.</b> 10/586,434
	<b>APPLICANT</b> Bondarev, et al.	
	<b>FILING DATE</b> January 18, 2005	<b>GROUP</b> Not Yet Assigned

## U.S. PATENT DOCUMENTS

Examiner Initial	Cite No.	Patent Number	Issue Date	Patentee	Class/ Subclass	Filing Date

## FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

Examiner Initial	Cite No.	Document Number	Publication Date	Country or Patent Office	Class/ Subclass	Translation Yes/No

## OTHER DOCUMENTS

(Including Author, Title, Date, Relevant Pages, Place of Publication)

Examiner Initial	Cite No.	
	DDB	Chen et al. (2001) Exp. Biol. Med. 226: 753-757.
	DDC	Delap et al. (1991) Proc. Annu. Meet. Am. Soc. Clin. Oncol. 10:A295.
	DDD	Doroshov et al. (1994) Proc. Annu. Meet. Am. Soc. Clin. Oncol. 13:146.
	DDE	Gomez et al. (1998) Biochemical Biophysical Res. Comm. 246:107-110.
	DDF	Reddel et al. (2001) Radiation Res. 155:194-200.
	DDG	Strahl et al. (1996) Molecular and Cell Biology 16:53-65.
	DDH	Gan et al. (2002) FEBS Lett. 527:10-14.
	DDI	Bocchetta et al. (2004) Oncogene 23:6484-6491.
	DDJ	Chabner et al. (2005) Nature Reviews Cancer 65-72.

EXAMINER	DATE CONSIDERED

**EXAMINER:** Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<b>FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (MODIFIED) U.S. PATENT AND TRADEMARK OFFICE</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (37 CFR 1.98(b))	<b>ATTY. DOCKET NO.</b> 04-40018-US1	<b>SER. NO.</b> 10/586,434
	<b>APPLICANT</b> Bondarev, et al.	
	<b>FILING DATE</b> January 18, 2005	<b>GROUP</b> Not Yet Assigned

## U.S. PATENT DOCUMENTS

Examiner Initial	Cite No.	Patent Number	Issue Date	Patentee	Class/ Subclass	Filing Date

## FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

Examiner Initial	Cite No.	Document Number	Publication Date	Country or Patent Office	Class/ Subclass	Translation Yes/No

## OTHER DOCUMENTS

(Including Author, Title, Date, Relevant Pages, Place of Publication)

Examiner Initial	Cite No.	
	DDK	Mathias et al. (1991) Science 254: 1808-1810.
	DDL	Wagner et al. (1997) Cancer Res. 57:2341-5.
	DDM	Hernandez and Perez (1997) J. Eur. Acad. Dermatol. Vener. 9:44-49.
	DDN	American Heritage Dictionary, 3 <sup>rd</sup> Ed., (2 pages).

EXAMINER	DATE CONSIDERED
/Jennifer Pitrak/	12/15/2010

**EXAMINER:** Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.